Study title: Comparison of the efficacy, safety and onset of action of mizolastine, cetirizine and placebo in the management of seasonal allergic rhinoconjonctivitis. Sabbah A et al (MIZOCET group). (Ann Allerg Asthm Immunol 1999 ; 83: 319-325) Publication 12 in CES DOSFILIRF-CES0386-EN-E01 - N. BLAY - 30/06/2005 Comparison of the efficacy, safety and onset of action of mizolastine, cetirizine and placebo in the management of seasonal allergic rhinoconjonctivitis. Sabbah A et al (MIZOCET group). (Ann Allerg Asthm Immunol 1999 ; 83: 319-325) Publication 12 in CES DOSFILIRF-CES0386-EN-E01 - N. BLAY - 30/06/2005
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: MIZOLASTINE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |